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Abstract 
Primary Sjögren’s syndrome (pSS) is a multi-system autoimmune disease with a 
prevalence and health economic impact that are comparable to rheumatoid arthritis. 
However, pSS research has been relatively poorly supported. The creation of a large 
cohort of clinically well-characterized pSS patients will provide a catalyst and valuable 
resources to promote high quality pSS research. In this review, we will describe the 
creation of such a cohort and the associated research biobank that is currently being 
established in the United Kingdom (UK) entitled United Kingdom primary Sjögren’s 
syndrome registry (UKPSSR). We will discuss the strengths and weaknesses of the 
design of the registry and highlight the key challenges in the establishment of the registry 
and the strategies that we employ to overcome these barriers. Finally, we will consider 
the future development of the UKPSSR including utilisation and maintenance of the 
cohort.  
Funding: Medical Research Council, UK (Grant No. G0800629). The cardiovascular sub-
study of the UKPSSR also receive support from the British Sjögren’s Syndrome 
Association. 
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Primary Sjögren’s syndrome is a significant healthcare burden  
Primary Sjögren’s syndrome (pSS) is a chronic multi-system disease affecting 
approximately 0.3-0.5% of the adult population in the western world, making it the 
second most common autoimmune rheumatic disease [1,2]. The true prevalence of pSS 
may be considerably higher because many patients may remain undiagnosed as their 
presenting complaints are often non-specific. Women are 9 times more likely to be 
affected than men [1-4]. The disease is characterised by oral and ocular dryness, fatigue 
and musculoskeletal pain. In addition, pSS can affect other organs including the kidneys, 
lungs, skin and the nervous system [3,4]. More importantly, patients with pSS have a 
greater than 40-fold increased risk of developing lymphoma [4, 5]. Patients with pSS 
have poor health-related quality of life and a significant proportion of pSS patients are 
unable to work due to their condition [2, 6-17]. In a recent study, a conservative estimate 
of the total annual indirect costs for patients with pSS was £7,677, comparable to that for 
patients with RA (£10,444) but significantly higher than that for healthy controls (£892) 
[18]. Therefore, pSS is not a benign condition, as often perceived by clinicians and non-
clinicians alike, but a significant health and economic burden to the patients and society.  
 
There is a large unmet need in pSS research and management of pSS patients 
The pathogenesis of pSS is unclear but is generally considered to be a consequence of 
autoimmunity. This conclusion is largely based on the observation of inflammatory 
infiltrates in the affected exocrine glands and the presence of characteristic 
autoantibodies against RNA-binding proteins Ro and La. What triggers the inflammatory 
response, however, is poorly understood. Furthermore, the pathophysiological basis for 
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the systemic manifestations of pSS such as fatigue and other organ involvement has not 
been defined. It is therefore unsurprising that no effective treatment is currently available 
for pSS. 
A literature search in February 2010 using Pubmed Central, the US National Institutes of 
Health digital archive of biomedical and life sciences journal literatures, retrieved 10,413 
articles when using the keywords “Sjogren’s syndrome” (and only 3066 if “primary 
Sjogren’s syndrome” was used), compared to 100,928 articles when the keywords 
“Rheumatoid arthritis” was used. The contrast was even more striking when the searches 
were limited to "humans" and “clinical trial”, with only 260 articles for “Sjogren’s 
syndrome” compared to 5940 for “rheumatoid arthritis”. While these measures are crude, 
it highlights the paucity of research in pSS considering the prevalence and health 
economic impact of a condition that has no effective treatment.  
The reasons for the lack of progress in pSS research are not clear but several possible 
explanations exist. Firstly, previous studies have often used different diagnostic criteria 
and outcome measures making comparison of data from different studies difficult. In 
addition, the sample sizes of many studies were often too small for meaningful 
conclusions to be drawn. Furthermore, detailed corresponding clinical data were often 
unavailable. Secondly, many clinical measurements of exocrine glandular function such 
as Schirmer’s test and unstimulated salivary flow do not have sufficient sensitivity to 
reliably distinguish pathophysiological processes of inflammatory activity, acinar gland 
damage or acinar cell loss. Furthermore, many patients with pSS often present late, hence 
researchers using samples from these patients may inadvertently limit their investigations 
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and thus bias their findings to the late-stages of the disease. Finally, pSS research has not 
received the level of public or commercial funding support of conditions such as RA.  
 
Taken together, these observations indicate that there is a large unmet need in pSS 
research and that additional infra-structure is necessary to support and stimulate high 
quality clinical and academic research into this disease. In this regard, the creation of a 
cohort of clinically well-characterised patients with pSS and the creation of a research 
biobank could provide a much needed resource and catalyst for pSS research.  
 
Recent advances in pSS research have created an optimal environment for the 
development of a national registry for pSS 
Despite the obstacles in pSS research set out above, some key progress has been made in 
pSS research over the last decade which has laid the foundation for a national cohort of 
pSS mentioned above. Firstly, through the effort of researchers in Europe and across the 
world, a consensus was reached on the classification criteria [19] for pSS and a core set 
of outcome assessment tools developed [20-26]. As a result, standardised approaches to 
data collection and analysis are now possible. Furthermore, these projects have 
galvanized the formation of the UK Sjögren’s Interest Group (UKSIG), a network of 
clinicians and scientists with an interest in pSS, as well as prompting the creation of 
many clinical databases of pSS patients among members from their own practices. 
Secondly, advances in clinical and laboratory investigative technologies including the 
emergence of high-throughput technologies such as proteomics and genomics which 
allow systematic analysis of genome composition and gene expression profiling has 
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opened up new avenues in dissecting the molecular basis of pSS and thus the potential for 
future, targeted drug development.  
 
The UK primary Sjögren’s syndrome registry 
The UK primary Sjögren’s syndrome registry (UKPSSR) is intended to be a cohort of 
500 clinically well-characterised patients with pSS fulfilling the AECG consensus 
criteria. The UKPSSR is funded by the Medical Research Council, UK. The primary 
objective of the UKPSSR is to promote high quality clinical research and facilitate 
clinical trials of pSS. In addition, it is hope that the establishment of the UKPSSR will 
foster collaborative research and enhance the profile of pSS research within a wider 
community.  
All patients recruited will be assessed for disease activity and damage, together with 
other detailed, relevant clinical information including data on quality of life using 
appropriate validated instruments. In addition, all cases will be assessed for their 
fulfilment of the AECG consensus criteria for pSS and cases that do not fulfil the criteria 
will be excluded. Table 1 summarises the clinical data that are being collected for the 
registry. All data, including subjective and objective clinical assessments and patient 
reported outcomes, are being collected using a standardised proforma. To facilitate 
clinical data collection, a web-based database has been developed so that recruiting 
clinicians have the option to enter the clinical data at source. This resource may reduce 
the risk of data loss during transfer and improve the efficiency of clinical data collection. 
In addition to clinical data collection, peripheral blood samples are taken from the 
participants for the extraction of serum, DNA and RNA which are stored for future 
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research. Therefore, the UKPSSR is more than a patient cohort, but also an 
epidemiological research project as well as a research biobank. 
Recruitment started in August 2009 and is due to complete in March 2012. There are 
currently 28 centres across the UK among the UKPSSR study group. However, new 
recruitment sites will be considered until the recruitment target is reached. The 
advantages of not limiting recruitment to a few large centres are two fold. First, it will 
increase the likelihood of achieving the recruitment target. Second, it will create a cohort 
that better represents the full spectrum of patients with pSS across the UK. However, 
quality assurance of a large number of recruiting sites can be problematic, and we will 
discuss how we address this issue later.  
Since the ultimate goal of the UKPSSR is to facilitate high-quality pSS research, it is 
important that all the resources of the UKPSSR (including the anonymised clinical data 
and biological materials) are widely accessible by researchers while at the same time to 
put in place a robust mechanism to ensure that the resources will only be used for high 
quality research, in particularly for the resources that are finite (e.g. serum and RNA). 
The strategies that we employed to achieve this goal are summarised in Table 2. 
 
Potential weaknesses of the UKPSSR 
While we believed that the UKPSSR is a highly meritorious project, we recognise that 
there are several potential weaknesses in its design. Firstly, we do not collect salivary 
gland biopsy samples, saliva or tears. Since the primary organs affected in pSS are the 
salivary and tear glands, studying the biopsy or other biological materials taken from 
these affected sites could be more informative in understanding the pathogenesis of pSS. 
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The collection of salivary gland biopsies was considered at the planning stage of the 
UKPSSR, however, the idea was abandoned because all the patients taking part in this 
study already have a definite diagnosis of pSS and salivary gland biopsy is therefore not 
clinically indicated. Furthermore, many of the recruiting centres do not have easy access 
to a salivary gland biopsy service. Regarding saliva, there was a debate on whether whole 
saliva or saliva directly collected from the major salivary glands was more appropriate 
and concerns were raised regarding the utility of saliva in pSS research. As for tear 
samples, we anticipated that collection of tears could be difficult or impossible for many 
patients, although impression cytology of the conjunctival cells may be an alternative. 
The need for collecting salivary gland biopsy, saliva and tear samples will be re-
evaluated during the interim data analysis when 250 patients are recruited. Secondly, as 
salivary gland biopsy is often not performed in the diagnostic algorithm for Sjögren’s 
syndrome in the UK, and because the AECG consensus criteria require the presence of 
either anti-Ro or -La antibodies or a positive salivary gland biopsy [19], we anticipate an 
over-representation of pSS patients with anti-Ro or –La antibodies in our cohort. Since 
the clinical features of anti-Ro/La+ pSS patients differ from those without the 
autoantibodies, the potential bias of anti-Ro/La+ pSS patients in the registry should be 
taken into account when the data are analyzed. Additionally, we will consider the 
creation of a smaller comparative cohort of anti-Ro/La- pSS patients in the future. 
Thirdly, the majority of the collaborating recruitment centres are secondary care 
rheumatology units, and since pSS patients without other systemic clinical manifestations 
may be managed by specialists in dentistry, oral medicine, ophthalmology or the general 
practitioners and not by rheumatologists, the UKPSSR could bias against patients with 
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predominantly dryness symptoms. Fourthly, since a large number of centres participate in 
the recruitment for this project and since the clinic settings of individual recruitment 
centres varies, recruiting clinicians can decide on the most efficient case finding strategy 
for their recruiting sites for pragmatic reason. However, we do recommend recruiting 
clinicians, if possible, to use their existing databases or clinic records in order to identify 
pSS patients under their care and send invitations to all such pSS patients to take part in 
this project to reduce the risk of under-ascertainment. Furthermore, all recruiting 
clinicians are required to maintain a screening log. Thus, our cases can either be 
identified through existing databases, or during routine clinical appointments or both. 
Recruiting clinicians who run a dedicated pSS clinic and those who use an active case 
ascertainment approach to identify cases are more likely to achieve complete case 
ascertainment. On the other hand, an ad hoc approach to identify cases is likely to result 
in under-ascertainment and may also affect the quality of the data obtained. In addition, 
this project requires patient consent which may lead to self-selection bias of pSS patients 
who are more motivated. Therefore, the UKPSSR is a convenience sample and subject to 
the potential sampling bias associated with this approach including non-representation of 
the population and did not identify the entire pSS population. However, the involvement 
of a large number of recruitment sites across the UK and the relatively large sampling 
size should reduce the risk of such bias associated with convenience sampling. 
Nevertheless, it is important that investigation of the factors that can affect case 
ascertainment should be carried out upon completion of recruitment and attempt should 
be made to correct such sampling bias when the data are analyzed. Fifthly, this is not an 
inception cohort and we anticipate that many patients of the UKPSSR cohort will have a 
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relatively long duration of the disease. However, as many patients with pSS often have 
many years of symptoms of dryness and other clinical manifestations such as fatigue and 
musculoskeletal pain before they seek medical advice, especially in a secondary care 
setting, it is a considerable challenge to accurately determine when the disease begins. 
Therefore, limiting the recruitment to “newly diagnosed” patients may not significantly 
improve the recruitment of patients with early disease, but instead will have a significant 
negative impact on recruitment rate. One approach that may facilitate the recruitment of 
patients with early stage of the disease is to screen all patients with sicca symptoms for 
pSS. In this regard, a recent study carried out in an early arthritis clinic in which anti-Ro 
and –La antibodies were routinely tested showed that while over 46% of patients reported 
sicca symptoms, none of the patients were positive for either the anti-Ro or anti–La 
antibodies. With the exception of one patient, none has undergone salivary gland biopsy 
(Hegarty et al, personal communication). Nevertheless, this observation suggests that the 
yield of diagnosing pSS according to AECG consensus criteria using this screening 
approach may be low, at least in an early arthritis clinic setting. It would be interesting to 
investigate whether such an approach may be more productive in oral medicine or 
ophthalmology clinics. It is also noteworthy that the Sjögren’s International Clinical 
Collaborative Clinical Alliance (SICCA) is setting up a research biobank and registry of 
patients and family members with sicca symptoms or other autoimmune features without 
the requirement of fulfilling the classification criteria of the AECG [27], it will be 
interesting to compare the data generated by the UKPSSR and that of the SICCA registry. 
Finally, the UKPSSR is a cohort of patients from the UK only, therefore, it remains 
possible that it is not representative of patients with pSS in other parts of the world, 
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although thus far, there is no strong evidence to suggest that there are significant 
geographical variations in the clinical features of pSS, at least within European 
populations. 
 
Challenges 
The key challenge for the UKPSSR is achieving the recruitment target. As of mid May 
2010, a total of 175 pSS patients have been recruited, 9 months after recruitment has 
started. Although the data appear to be encouraging, a closer examination of the data 
revealed that there are only 10 centres actively recruiting, 5 centres in the preparation 
stage for recruitment, but almost half of the recruiting centres have not yet obtained the 
necessary regulatory requirement for taking part in recruitment, including several centres 
that are anticipated to recruit a high number of patients. The lengthy delay in obtaining 
the relevant regulatory approvals for this project was unexpected. Although under the 
Research Governance Framework in the UK, there is no requirement for local approval 
from the Research and Development (R&D) department of the recruitment centres, 
however, in practice, because of the potential impact on clinical services of the 
recruitment centres, approvals from the local R&D department is essential for most 
recruitment sites. In the UK, the infra-structure support for clinical research is provided 
by the UK National Institute of Health Research (NIHR). The recent changes to the 
NIHR funding strategies for clinical research means that funding for and access to the 
clinical research support infra-structure such as research nurses, clinic time and space, 
will be limited to studies that have been adopted as approved “portfolio” studies by the 
NIHR comprehensive local research networks (CLRN). The aim of the “adoption 
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process” is to ensure that the funding will be used to support only high quality clinical 
research projects. However, this has created a significant barrier for the UKPSSR 
recruitment because although the registry is clearly created with the aim of facilitating 
clinical and academic research, and will generate invaluable epidemiological data, it 
lacks a "clearly defined" research question to be addressed. Such a question is an 
essential requirement for the study to be approved by the UK NIHR CLRN and 
consequently the UKPSSR has not been adopted into the portfolio of the NIHR approved 
studies to date. This fact has had important repercussions for our recruitment sites as 
many are heavily reliant on the support of the clinical research infra-structure in order to 
take part in recruitment. To circumvent this obstacle, the UKPSSR has made a further 
application for NIHR CLRN approval using a substudy of the registry which is designed 
to assess the cardiovascular risk of pSS patients. This substudy has now been approved as 
a NIHR portfolio study. Since the substudy is a study that utilises the majority of the 
clinical data/samples collected for the UKPSSR main study with additional study-specific 
assessment, in practical terms, the UKPSSR project has now been approved by the NIHR 
CLRN. We anticipate that this approval will have a significant beneficial impact on the 
progress on gaining local R&D approvals as well as attracting new recruitment sites. 
Another major challenge is to quality assure the UKPSSR data and samples especially 
when a large number of centres are involved in the recruitment. Several measures are 
used to ensure the robustness of our data and quality of our samples. Firstly, during the 
set-up phrase of the registry, we held a series of meeting inviting all the recruiting 
clinicians and patient representatives to discuss all aspects concerning the recruitment 
process such as the design of the proforma and database, patient identification and 
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selection, the organisation of recruitment, data and sample collection and strategies to 
secure research infra-structure support. This consultation process helped to develop a 
protocol that is as feasible and practical as possible without compromising the design of 
the registry. Secondly, adequate training and support for recruiting staff is provided. This 
is accomplished through group training meetings, one-to-one training during initiation 
site-visits and opportunity for recruiting staff to “shadow” the recruitment process. In 
addition, a dedicated senior research nurse for the registry will provide support and 
answer queries regarding the recruitment procedure. Thirdly, formal written agreements 
and protocol are set up. Regarding the samples, supply agreements are in place between 
the UKPSSR and the recruitment centres defining the standards expected of the 
procurement procedures and the transfer of the samples as well as the responsibility of 
the recruiting sites and the receiving organisation. In addition, standard operation 
procedures are in place to cover all aspects of the recruitment procedures. Nevertheless, 
in this project, comprehensive clinical information is being collected which can be 
particularly challenging if patients are recruited during routine outpatient appointments. 
Therefore, the recruiting clinicians need to be highly motivated, vigilant and dedicated. 
Furthermore, the quality of the clinical data will also depend on the quality of the medical 
records available at source. Therefore, another key measure for quality assurance is 
monitoring and audit. In this regard, all the data will be checked for accuracy and 
completeness. Any mishandling of the samples is recorded and an audit trail will be kept. 
Formal audit will be carried out at least once during the lifetime of the project. 
Another important challenge for the UKPSSR is to maximise the utilisation of the cohort 
and the resource of the UKPSSR for high quality pSS research. To date, the cohort is 
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being used for a mixture of ongoing clinical and academic projects including the 
assessment of cardiovascular risk in pSS, the investigation of the link between anti-
muscarinic receptor and pSS, genetic association studies organised by the Sjögren’s 
Genetics Network as well as the validation of pSS assessment tools organised by the 
European League Against Rheumatism (EULAR) Sjögren’s syndrome study group. In 
addition, the cohort will also be utilised for patient selection for a planned multi-centre 
randomised placebo-controlled clinical trial of rituximab in patients with pSS. We have 
outlined earlier the strategies that we use to maximise the utilisation of the cohort in Box 
2, but it remains to be seen how effective these strategies will be. In particularly, one of 
the strategies is to create a parallel cohort of age-, sex- and gender-matched healthy 
controls. Thus far, the rate of healthy controls is relatively slow with just under 20 
participants after a six-month recruitment period. This is partly because our current 
emphasis on achieving the recruitment target for pSS patients, but may also be a result of 
the recruitment method used. Currently we use the “find a friend” approach, in an attempt 
to create a cohort that is not only age-, sex- and gender-matched, but also matches for 
geographical and social parameters. Nevertheless, contingency plan is in place for 
healthy controls recruitment through open advertisement in key recruitment centres if our 
recruitment target is not reached.  
Finally, a longer term challenge for the UKPSSR is the maintenance and development of 
the cohort as well as the long-term storage of the samples which will require securing of 
further funding to support the necessary personnel and consumables cost. 
 
Future development 
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Our vision is that the UKPSSR will be the foundation of a long-term collaborative 
project. Therefore, it is important that we look ahead to the future development of the 
registry. Firstly, we plan to collect longitudinal data at 3-5 years after the inception, and 
every 5 years subsequently. In this regard, the UKPSSR is modelled on a successful 
rheumatology cohort, the Norfolk Arthritis Register [28]. Longitudinal study of the 
cohort will not only generate valuable data on the natural history of pSS, which is at 
present poorly understood, but also important in the evaluation of systemic features such 
as pulmonary manifestations, peripheral neuropathy and lymphomas which are more 
common in patients with longer disease duration [29, 30]. In addition, the creation of a 
disease-control cohort will facilitate the utilisation of the UKPSSR data and samples. 
Suitable disease controls may include patients with secondary Sjögren's syndrome or 
other connective diseases such as lupus and rheumatoid arthritis (with or without 
secondary SS). Furthermore, it may be desirable to develop additional smaller pSS 
cohorts with particular clinical features such as an “inception cohort”, “anti-Ro/La- 
cohort” and a “systematic population sampling cohort” in order to address some of the 
potential weaknesses relating to the sampling methods used in the creation of UKPSSR. 
As mentioned earlier, we have developed a web-based database for clinical data 
collection for the UKPSSR. We envisage that the data from the registry will guide us to 
develop a simplified downloadable version for clinicians to use for their day-to-day 
management of pSS patients. This database will not only improve the standard of care of 
pSS patients but also facilitate standardisation of data collection which in turn will 
facilitate future research and clinical audits.  
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Thirdly, we hope to form a collaborative network with other pSS registries across the 
world and to reach a consensus on a core data set that is important for all pSS registries. 
Such a consensus can promote data sharing, increase the power of the data analysis and 
ultimately benefits pSS research and patient care. 
 
Conclusions  
To conclude, the UKPSSR will enhance pSS research through facilitating clinical and 
academic studies as well as generating an invaluable set of epidemiological data. The 
registry could bias against pSS patients negative for anti-Ro and La antibodies, and the 
lack of salivary gland samples could reduce the utility of the biobank. The key challenge 
for the UKPSSR is achieving the recruitment target and ensuring the standards of the data 
and samples collected are high. The difficulty was compounded by the delay in obtaining 
the relevant regulatory approvals and the potential loss of clinical research infra-structure 
support in some recruitment centres. Therefore, it is clear that the creation of the 
UKPSSR required the enthusiasm, commitment and hard work of all the UKPSSR study 
group members. The ultimate success of the UKPSSR, however, will be measured by its 
utilisation for high quality pSS research and the future development of the cohort. In the 
longer term, it is hoped that the UKPSSR will serve as a foundation for the formation of a 
more extensive collaborative research network for pSS. 
 
Key Messages 
1. UKPSSR is a national cohort and research biobank of 500 clinically well-characterised 
pSS patients. 
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2. Key challenges are archiving the recruitment target and quality assurance of the data 
and samples. 
3. The success of the UKPSSR will be assessed by its utilisation for pSS research. 
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Clinician’s Assessment Patient Reported Outcome 
1. AECG consensus criteria 
 
2. Demographics 
 
3. Treatment (pharmacological and non-
pharmacological) 
 
4. Co-morbidity 
 
5. Disease activity* 
- ESSDAI 
- SCAI 
- SSDAI 
 
6. Disease damage 
- SDI 
- SSDDI 
Optional 
7. Cardiovascular risk assessment 
 
1. Symptom assessment 
- PROFAD-SSI 
- ESSPRI 
- Epworth Sleepiness Scale 
- Orthostatic symptoms scale 
 
2. Quality of life 
- EQ-5D 
- SF-36 
 
3. Anxiety and depressive symptoms 
- HAD 
Optional 
4. Autonomic symptoms and cardiovascular risk 
- COMPASS 
- Lifestyle (smoking, physical activity) 
 
Table 1. The categories of clinical data that are collected for the UKPSSR and the outcome measure 
tools used for the data collection. Abbreviations: ESSDAI, SCAI, SSDAI, SDI, SSDDI, PROFAD-SDI, 
ESSPRI – see main text. EQ-5D: European Quality of life–5 dimensions, SF-36: Short form 36, HAD: 
Hospital anxiety and depression scale, COMPASS: Composite autonomic symptom scale. 
 Strategies 
1.Removing Barriers 
 
1. Obtain "generic" research ethics approval for the use of the UKPSSR 
resources for research directly relevant to pSS 
2. Improving 
Accessibility 
1. Open access to all academic institutions and industrial partners both within 
the UK and abroad. 
2. Set up a website for the registry (www.sjogrensregistry.org) 
3. Active engagement with researchers who have the expertise and interest in 
pSS research 
4. Promotion of the UKPSSR at appropriate medical and scientific conferences 
3. Quality Assurance 
of research projects 
1. Formal application for the use of the UKPSSR is required 
2. Applications reviewed by a 7 person steering committee to assess the 
scientific merits and relevance to pSS research 
3. Samples and data will only be released after evidence of adequate financial 
support and all necessary regulatory approvals are obtained 
4. All samples released will be subject to material transfer agreements which 
ensure that samples are used for specified project, and that the samples will 
be handled appropriately and in strict confidence 
4. Added values 1. UKPSSR can request the researchers utilising the samples/data to send a 
copy of the data derived if the steering committee judge that the addition of 
such data will enhance the utilisation of UKPSSR.  
2. Establish an age-, gender- and ethnicity-matched healthy control cohort. 
(The creation of a suitable disease control cohort and other pSS subset is 
under consideration). 
5. Maintenance of 
high quality samples 
1. SOPs for sample collections, processing and storage 
2. Use PAXgene collection tubes to ensure high quality DNA & RNA samples 
3. Generate EBV transformed cell lines to maintain a permanent source of 
DNA 
 
Box 2. The strategies for promoting the utilisation of the UKPSSR resources for high quality pSS 
research. 
